From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
Chronic Hepatitis b
Interventions
DRUG

Terbinafine

terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.

DRUG

Placebo

Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.

DRUG

Tenofovir

Tenofovir 245mg standard of care

Trial Locations (1)

1105AZ

RECRUITING

Amsterdam UMC, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER